FluoGuide has received approval to commence with FG001 in evening dosing in the ongoing clinical phase I/II trial in patients with high grade glioma
Copenhagen, Denmark, 12 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Danish Medicines Agency and Ethical Committee has approved administration of FG001 in the evening before surgery.The data from the ongoing dose finding trial suggests that background light intensity might be further reduced if FG001 is administered in the evening prior to surgery. This would presumably give an even better image quality and tumor delineation. To ensure that the best possible combination of FG001 dose and time of administration is carried forward in clinical